Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 7387 

needed by CMS to support the MDPP 

benefit. Based on experience with the 

DPRP from 2011–2020, including data 

analysis, and feedback from applicant 

organizations and internal and external 

partners, CDC plans to revise the DPRP 

Standards and the associated 

information collection. 

Key changes are a direct result of 

DPRP data analyses and discussion with 

National DPP stakeholders, including 

those serving vulnerable populations. 

Key changes allow for the optional 

collection of Hemoglobin A1C levels, 

and for weight/physical activity minutes 

to be combined (a new method), to 

determine Full recognition; the required 

collection of Application Delivery Mode 

questions; revised organizational type 

information; program enrollment 

motivation/enrollment source 

information; adding Gender; and the 

removal of Session ID. Three data 

elements have been minimally revised 

and no other data elements have been 

added to the one-time application form; 

and, three have been revised, one has 

been deleted, and four have been added 

to the evaluation data elements, as per 

below: 

Application Form 

(1) Delivery Mode- follow-up questions 

(revised) 

(2) Class Type (revised) 

(3) Organization Type (revised) 

Evaluation Data Elements 

(4) Enrollment Motivation (new) 

(5) Enrollment Source (revised) 

(6) Session ID (deleted) 

(7) HBA1C Value (new) 

(8) Participant’s Gender (new) 

During the period of this Revision, 

CDC estimates receipt of approximately 

300 DPRP application forms per year. 

The estimated burden per one-time, upfront application response is one hour. 

CDC further estimates receipt of semiannual evaluation data (two hours at 

each submission) from the new 300 

organizations per year plus existing 

organizations who also submit semiannual evaluation data. The total 

estimated average annualized evaluation 

burden to respondents is 8,700 hours. 

This includes an estimate of the time 

needed to extract and compile the 

required data records and fields from an 

existing electronic database, review the 

data, create or enter a data file in the 

required format (i.e., CSV file), and 

submit the data file via the National 

DPP website for upload into the DPRP 

Data Portal. The estimated burden per 

response is modest since the 

information requested for DPRP 

recognition is routinely collected by 

most organizations that deliver lifestyle 

change programs for their own internal 

evaluation and possible insurance 

reimbursement purposes, including 

Medicare under the MDPP benefit. 

Participation in the DPRP is voluntary, 

data are de-identified, no Personally 

Identifiable Information (PII) is 

collected by CDC, and there are no costs 

to respondents other than their time. 

CDC is requesting a three-year approval. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondents Form name Number of respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Public sector organizations that deliver type 2 

diabetes prevention programs.

DPRP Application Form .................................

DPRP Evaluation Data ...................................

90 

630 

1 

2 

1 

2 

Private sector organizations that deliver type 

2 diabetes prevention programs.

DPRP Application Form .................................

DPRP Evaluation Data ...................................

210 

1470 

1 

2 

1 

2 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–01915 Filed 1–27–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Requirement for Negative PreDeparture COVID–19 Test Result or 

Documentation of Recovery From 

COVID–19 for all Airline or Other 

Aircraft Passengers Arriving Into the 

United States From Any Foreign 

Country 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of Agency Order. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS) announces an 

Agency Order requiring negative predeparture COVID–19 test results or 

documentation of recovery from 

COVID–19 for all airline or other aircraft 

passengers arriving into the United 

States from any foreign country. This 

Order was signed by the CDC Director 

on January 25, 2021 and supersedes the 

previous Order signed by the CDC 

Director on January 12, 2021. 

DATES: This Order was effective January 

26, 2021. 

FOR FURTHER INFORMATION CONTACT: 

Jennifer Buigut, Division of Global 

Migration and Quarantine, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H16–4, Atlanta, 

GA 30329. Email: dgmqpolicyoffice@

cdc.gov. 

SUPPLEMENTARY INFORMATION: This 

Order prohibits the introduction into 

the United States of any aircraft 

passenger departing from any foreign 

country unless the passenger: (1) Has a 

negative pre-departure test result for 

SARS–CoV–2, the virus that causes 

COVID–19 (Qualifying Test); or (2) 

written or electronic documentation of 

recovery from COVID–19 after previous 

SARS–CoV–2 infection in the form of a 

positive viral test result and a letter 

from a licensed health care provider or 

public health official stating that the 

passenger has been cleared for travel 

(Documentation of Recovery). 

This Order supersedes the previous 

Order signed by the CDC Director on 

January 12, 2021. This Order further 

clarifies the exemption categories for 

federal law enforcement and U.S. 

Department of Defense (DOD) personnel 

observing DOD precautions to prevent 

the transmission of COVID–19 during 

travel. This Order also replaces the 

previous language concerning the ability 

of airlines and aircraft operators to 

request specific waivers and replaces it 

with a limited humanitarian exemption 

category allowing individuals and 

organizations to request an exemption. 

To be eligible for this limited 

humanitarian exemption, the individual 

or organization must demonstrate both: 

(1) Exigent circumstances where 

emergency travel is required to preserve 

health and safety (e.g., emergency 

7388 Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 

1This Order supersedes the previous order signed 

by the U.S. Centers for Disease Control and 

Prevention (CDC) Director on January 12, 2021. 

2CDC encourages airline or aircraft operator to 

incorporate the attestation into paperless check-in 

processes. Airline or aircraft operator may use a 

third party (including a third-party application) to 

collect attestations, including to provide 

translations. But airline or aircraft operator has sole 

legal responsibility to provide and collect 

attestations, to ensure the accuracy of any 

translation, and to comply with all other obligations 

under this Order. Airline or aircraft operator is 

responsible for any failure of a third party to 

comply with this Order. Airline or aircraft operator 

may not shift any legal responsibility to a third 

party. 

3Health care providers and public health officials 

should follow CDC guidance in clearing patients for 

travel to the United States. Applicable guidance is 

available at https://www.cdc.gov/coronavirus/2019- 

ncov/hcp/disposition-in-home-patients.html. 

4https://www.cdc.gov/coronavirus/2019-ncov/ 

hcp/duration-isolation.html. 

medical evacuations); and (2) that 

predeparture testing cannot be accessed 

or completed before travel. No changes 

were made to the Passenger Attestation. 

This Order constitutes a controlled 

free pratique to any airline or other 

aircraft operator with an aircraft arriving 

into the United States. Pursuant to this 

controlled free pratique, the airline or 

other aircraft operator must comply 

with the conditions outlined in the 

Order. 

A copy of the Order is provided 

below. A copy of the signed Order and 

Passenger Attestation can be found at 

https://www.cdc.gov/quarantine/frproof-negative-test.html. 

Centers for Disease Control and 

Prevention, Department of Health and 

Human Services 

Order Under Section 361 of the Public 

Health Service Act (42 U.S.C. 264) and 

42 Code of Federal Regulations 71.20 & 

71.31(b) 

Requirement for Negative PreDeparture COVID–19 Test Result or 

Documentation of Recovery From 

COVID–19 for all Airline or Other 

Aircraft Passengers Arriving Into the 

United States From any Foreign 

Country 1

Summary 

Pursuant to 42 CFR 71.20 and as set 

forth in greater detail below, this Notice 

and Order prohibit the introduction into 

the United States of any aircraft 

passenger departing from any foreign 

country unless the passenger: (1) Has a 

negative pre-departure test result for 

SARS–CoV–2, the virus that causes 

COVID–19 (Qualifying Test); or (2) 

written or electronic documentation of 

recovery from COVID–19 after previous 

SARS–CoV–2 infection in the form of a 

positive viral test result and a letter 

from a licensed health care provider or 

public health official stating that the 

passenger has been cleared for travel 

(Documentation of Recovery). 

The negative pre-departure test must 

be a viral test that was conducted on a 

specimen collected during the 3 days 

preceding the flight’s departure from a 

foreign country (Qualifying Test). 

Alternatively, if the passenger has 

recovered from COVID–19, the 

passenger may instead travel with 

written or electronic documentation of a 

positive viral test result that confirms 

previous SARS–CoV–2 infection and a 

letter from a licensed health care 

provider or public health official stating 

that the passenger has been cleared for 

travel (Documentation of Recovery). A 

passenger must retain written or 

electronic documentation reflecting the 

negative Qualifying Test result or 

Documentation of Recovery presented to 

the airline or other aircraft operator. A 

passenger must also produce such 

Qualifying Test result or Documentation 

of Recovery upon request to any U.S. 

government official or a cooperating 

state or local public health authority. 

Pursuant to 42 CFR 71.31(b) and as set 

forth in greater detail below, this Notice 

and Order constitute a controlled free 

pratique to any airline or other aircraft 

operator with an aircraft arriving into 

the United States. Pursuant to this 

controlled free pratique, the airline or 

other aircraft operator must comply 

with the following conditions to receive 

permission for the aircraft to enter and 

disembark passengers in the United 

States: 

• Airline or other aircraft operator 

must verify that every passenger—2 

years of age or older—onboard the 

aircraft has attested to receiving a 

negative Qualifying Test result or to 

having recovered from COVID–19 after 

previous SARS–CoV–2 infection and 

being cleared to travel by a licensed 

health care provider or public health 

official. 

• Airline or other aircraft operator 

must confirm that every passenger 

onboard the aircraft has documentation 

of a negative Qualifying Test result or 

Documentation of Recovery from 

COVID–19. 

Statement of Intent 

This Order shall be interpreted and 

implemented to achieve the following 

paramount objectives: 

• Preservation of human life; 

• Preventing the further introduction, 

transmission, and spread of the virus 

that causes COVID–19 into the United 

States, including new virus variants; 

• Preserving the health and safety of 

crew members, passengers, airport 

personnel, and communities; and 

• Preserving hospital, healthcare, and 

emergency response resources within 

the United States. 

Definitions 

Aircraft shall have the same definition 

as under 42 U.S.C. 40102(a)(6). 

‘‘Aircraft’’ includes, but is not limited 

to, commercial, general aviation, and 

private aircraft destined for the United 

States from a foreign country. 

Aircraft Operator means an individual 

or organization causing or authorizing 

the operation of an aircraft. 

Airline shall have the same definition 

as under 42 CFR71.1(b). 

Attest/Attestation means having 

completed the attestation in Attachment 

A. Such attestation may be completed in 

written or electronic form. The 

attestation is a statement, writing, entry, 

or other representation under 18 U.S.C. 

1001.2

Confirm that every passenger onboard 

the aircraft has documentation 

reflecting a negative Qualifying Test 

result means confirmation that: 

(1) The personal identifiers (e.g., name and 

date of birth) on the negative Qualifying Test 

result match the personal identifiers on the 

passenger’s passport or other travel 

documents; 

(2) if the passenger is arriving on a direct 

flight to the United States, the specimen was 

collected within the 3 days preceding the 

flight’s departure; 

(3) if the passenger is arriving via one or 

more connecting flights the specimen was 

collected within the 3 days preceding the 

departure of the initial flight; 

(4) the test performed was a viral test (as 

defined below); and 

(5) the test result states ‘‘NEGATIVE,’’ 

‘‘SARS–CoV–2 RNA NOT DETECTED,’’ 

‘‘SARS–CoV–2 ANTIGEN NOT DETECTED,’’ 

or ‘‘COVID–19 NOT DETECTED.’’ A test 

marked ‘‘invalid’’ is not acceptable. 

Confirm that a passenger alternatively 

has written or electronic documentation 

of recovery from COVID-19 means 

confirmation that: 

(1) The passenger has presented 

documentation of a positive test result and a 

signed letter on official letterhead that 

contains the name, address, and phone 

number of a licensed healthcare provider or 

public health official stating that the 

passenger has been cleared for travel; 3

(2) the positive test result occurred within 

the last three months (90 days) preceding the 

passenger’s flight to the United States, or at 

such other intervals as specified in CDC 

guidance; 4

(3) the personal identifiers (e.g., name and 

date of birth) on the positive test result and 

signed letter match the personal identifiers 

on the passenger’s passport or other travel 

documents; 

(4) the test performed was a viral test (as 

defined below); and 

Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 7389 

5https://www.faa.gov/other_visit/aviation_

industry/airline_operators/airline_safety/safo/all_

safos/media/2020/SAFO20009.pdf. Airlines, 

aircraft operators, and their crew members may 

follow even stricter protocols for safety, including 

testing protocols. 

6 Interim Guidance for Transporting or Arranging 

Transportation by Air into, from, or within the 

United States of People with COVID–19 or COVID– 

19 Exposure available at https://www.cdc.gov/ 

quarantine/interim-guidance-transporting.html. 

7https://www.gov.uk/government/news/pheinvestigating-a-novel-variant-of-covid-19. 

8https://www.ecdc.europa.eu/en/publicationsdata/threat-assessment-brief-rapid-increase-sarscov-2-variant-united-kingdom. 

(5) the test result states ‘‘POSITIVE,’’ 

‘‘SARS–CoV–2 RNA DETECTED,’’ ‘‘SARS– 

CoV–2 ANTIGEN DETECTED,’’ or ‘‘COVID– 

19 DETECTED.’’ A test marked ‘‘invalid’’ is 

not acceptable. 

Foreign country means anywhere that 

is not a state, territory, or possession of 

the United States. 

Negative Pre-departure Test Result for 

COVID–19 or negative Qualifying Test 

result means documentation of a 

negative COVID–19 test taken within 

the 3 days preceding a flight’s 

departure. Such documentation may be 

in paper or electronic format as required 

by this Order. Testing must be 

performed using a viral test. The 

documentation must also include 

sufficient verification information— 

such as the name and contact 

information for the laboratory or 

healthcare personnel who performed the 

test. 

Viral test means a viral detection test 

for current infection (i.e., a nucleic acid 

amplification test or a viral antigen test) 

approved or authorized by the relevant 

national authority for the detection of 

SARS–CoV–2. 

United States has the same meaning 

as ‘‘State’’ and ‘‘U.S. Territory’’ in 42 

CFR 71.1(b). 

Exemptions 

The following categories of 

individuals and organizations are 

exempt from the requirements of this 

Order: 

• Crew members of airlines or other 

aircraft operators provided that they 

follow industry standard protocols for 

the prevention of COVID–19 as set forth 

in relevant Safety Alerts for Operators 

(SAFOs) issued by the Federal Aviation 

Administration (FAA).5

• Airlines or other aircraft operators 

transporting passengers with COVID–19 

pursuant to CDC authorization and in 

accordance with CDC guidance.6

• Federal law enforcement personnel 

on official orders who are traveling for 

the purpose of carrying out a law 

enforcement function, provided they are 

covered under an occupational health 

and safety program in accordance with 

CDC guidance. Those traveling for 

training or other business purposes 

remain subject to the requirements of 

this Order. 

• U.S. Department of Defense (DOD) 

personnel, including military personnel 

and civilian employees, dependents, 

contractors (including whole aircraft 

charter operators), and other U.S. 

government employees when traveling 

on DOD assets, provided that such 

individuals are under competent 

military or U.S. government travel 

orders and observing DOD precautions 

to prevent the transmission of COVID– 

19 as set forth in Force Protection 

Guidance Supplement 14—Department 

of Defense Guidance for Personnel 

Traveling During the Coronavirus 

Disease 2019 Pandemic (December 29, 

2020) including its testing guidance. 

• Individuals and organizations for 

which the issuance of a humanitarian 

exemption is necessary based on both 

(1) exigent circumstances where 

emergency travel is required to preserve 

health and safety (e.g., emergency 

medical evacuations) and (2) where predeparture testing cannot be accessed or 

completed before travel. Additional 

conditions may be placed on those 

granted such exemptions, including but 

not limited to, observing precautions 

during travel, providing consent to postarrival testing, and/or self-quarantine 

after arrival in the United States, as may 

be directed by federal, state, territorial, 

tribal or local public health authorities 

to reduce the risk of transmission or 

spread. 

Background 

The COVID–19 pandemic has spread 

throughout the world. Individuals who 

travel may be at risk for exposure to 

SARS–CoV–2 before, during, and after 

travel. This could result in U.S.-bound 

travelers further spreading the virus to 

others during travel, upon arrival in the 

United States, and at their destinations. 

Over the last few weeks, the United 

Kingdom (UK) has faced a rapid 

increase in COVID–19 cases in South 

East England, leading to enhanced 

epidemiological and virological 

investigations. On December 14, 2020, 

Public Health England announced that a 

new variant of SARS–CoV–2 had been 

identified across the southeast of 

England.7 Preliminary analysis in the 

UK suggests that this SARS–CoV–2 

variant may be more transmissible than 

previously circulating variants, with an 

estimated potential to increase the 

reproductive number (R0) by 0.4–0.7 or 

greater with an estimated increased 

transmissibility of up to 70 percent.8

On December 19, 2020, in response to 

the emergence of the UK variant, the 

countries comprising the UK announced 

stricter measures to be applied from 

December 20 and over the coming 

weeks, with affected areas entering a 

‘Tier 4’ level with movement 

restrictions within and between more 

and less heavily affected areas. These 

measures have included 

recommendations for residents of the 

most affected areas to restrict 

movements and travel, including 

international travel, outside of these 

areas. The government of Scotland 

announced a travel ban between 

Scotland and the rest of the UK. In 

addition, the Netherlands issued a travel 

ban from the UK effective through 

January 1, 2021, and Belgium 

temporarily halted flight and train travel 

from the UK. Other countries took 

similar measures to restrict travel from 

the UK. 

A second new variant of SARS–CoV– 

2 was reported in the Republic of South 

Africa (RSA) on December 18, 2020, that 

also appears to spread more rapidly 

than earlier variants of the virus. The 

RSA variant is distinct from the UK 

variant but shares a mutation in the 

spike protein that appears to increase 

transmissibility. Since being identified, 

the new variant has spread inland from 

coastal regions of RSA and has become 

the predominant variant in some areas 

of the country. 

During December 21–26, 2020, several 

countries implemented restrictions on 

travel from South Africa, including 

China, El Salvador, Germany, 

Guatemala, Israel, Panama, Sudan, 

Switzerland, Turkey, and the UK. The 

Netherlands imposed a ban on travel 

from RSA on December 21 but lifted the 

ban for both the UK and RSA on 

December 23, stating that travelers will 

instead need to present a negative 

COVID–19 test result obtained within 72 

hours of their scheduled arrival in the 

Netherlands, followed by 10 days of 

self-quarantine. On December 28, Japan 

imposed a ban on entry of all foreign 

nationals through the end of January 

2021. On December 28, the Government 

of South Africa announced new 

restrictions on businesses and public 

movement. As of January 7, 2021, 

Canada requires air passengers 5 years 

of age or older to test negative for 

COVID–19 before arrival. On January 8, 

the United Kingdom announced a predeparture testing requirement for all 

inbound international travelers with 

limited exceptions; a 10-day post-arrival 

quarantine will still be required. 

On December 25, 2020, CDC issued an 

Order requiring proof of a negative 

Qualifying Test result for all airline 

7390 Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 

9Runway to Recovery 1.1, December 21, 2020, 

available at https://www.transportation.gov/ 

briefing-room/runway-recovery-11. 

10https://www.cdc.gov/coronavirus/2019-ncov/ 

travelers/testing-air-travel.html. 

11 Johansson MA, Wolford H, Paul P, et al. 

Reducing travel-related SARS–CoV–2 transmission 

with layered mitigation measures: Symptom 

monitoring, quarantine, and testing, available at 

https://www.medrxiv.org/content/10.1101/ 

2020.11.23.20237412v1. 

12https://www.cdc.gov/coronavirus/2019-ncov/ 

hcp/duration-isolation.html. 

13https://www.cdc.gov/coronavirus/2019-ncov/ 

travelers/after-travel-precautions.html. 

passengers arriving from the UK to the 

United States. Since then, cases of the 

UK and RSA variants have been 

discovered in four Canadian provinces, 

including in individuals with no travel 

history indicating spread in Canada. 

The UK variant has also been found in 

at least 50 countries and the RSA 

variant has also been detected in at least 

15 countries. The first case of the UK 

variant in the United States was found 

in Colorado on December 29, in an 

individual with no known travel 

history. On December 30, a second case 

was reported in California. Since then, 

the UK variant strain has accounted for 

144 cases in 20 U.S. states. Another new 

variant strain of concern initially 

detected in South America in March 

2020 has been detected in at least 19 

countries on 5 continents through late 

December and has mutations in the 

spike protein that raise concerns of 

increased infectivity. 

While it is known and expected that 

viruses constantly change through 

mutation leading to the emergence of 

new variants, these new variants have 

emerged at a time when numbers of new 

cases in the United States have 

continued to increase at alarming rates. 

Additional new virus variants are also 

likely to emerge as the virus continues 

to evolve and mutate. Accordingly, 

further action is needed to help mitigate 

the spread of these and other new virus 

variants into the United States. 

Based on increased transmissibility 

and spread of these new variants of 

SARS–CoV–2, and to reduce 

introduction and spread of these and 

future SARS–CoV–2 variants into the 

United States, expanding current UK 

pre-departure testing requirements to all 

foreign countries and U.S.-bound 

passengers is warranted. This approach 

to testing-based risk assessment has 

been addressed in CDC guidance and 

the Runway to Recovery guidance 

jointly issued by the Departments of 

Transportation, Homeland Security, and 

Health and Human Services.9 Testing 

for SARS–CoV–2 infection is a proactive 

approach and not dependent on the 

infecting strain. Approximately 120 

countries now use testing in some form 

to monitor risk and control introduction 

and spread. With case counts and 

deaths due to COVID–19 continuing to 

increase around the globe and the high 

proportion of infected people with 

asymptomatic or pre-symptomatic 

infections, the United States must take 

a dual approach to combatting the virus. 

This means concurrently mitigating and 

slowing the introduction and spread of 

SARS–CoV–2 and controlling 

transmission within U.S. communities 

that are currently being overwhelmed by 

a surge in infections, hospitalizations, 

and deaths. 

Pre-departure testing may detect 

travelers infected with SARS–CoV–2 

before they initiate their travel. CDC 

recommends viral testing and receipt of 

results 1–3 days 10 before departure for 

international travelers, particularly 

those traveling long distances or passing 

through transportation hubs such as 

airports where social distancing may be 

challenging. CDC modeling indicates 

that pre-departure testing is most 

effective when combined with selfmonitoring.11 Testing before departure 

results in the greatest reduction of 

transmission risk during travel when the 

specimen is collected close to the time 

of departure. Earlier testing (i.e., more 

than 3 days before travel) provides little 

benefit beyond what self-monitoring 

alone can provide. 

For persons previously diagnosed 

with COVID–19 who remain 

asymptomatic after recovery, CDC does 

not recommended retesting within 3 

months after the date of symptom onset 

(or the date of first positive viral 

diagnostic test if their infection was 

asymptomatic) for the initial SARS– 

CoV–2 infection.12 Persons who develop 

any symptoms of COVID–19 during this 

time period should not travel and seek 

care for testing and evaluation. This 

guidance may be updated as additional 

information about people who have 

recovered from COVID–19 becomes 

available. 

Pre-departure testing does not 

eliminate all risk. However, when predeparture testing is combined with 

other measures such as self-monitoring 

for symptoms of COVID–19, wearing 

masks, social distancing, and hand 

hygiene, it can make travel safer by 

reducing spread on conveyances, in 

transportation hubs, and at destinations. 

For international air travelers and others 

with higher risk of exposure, CDC 

additionally recommends a post-arrival 

test 3–5 days after arrival at destination, 

combined with self-monitoring and a 7- 

day period of staying home (or in a 

comparable location such as a hotel 

room) to further reduce the risk of 

translocating the virus into destination 

communities.13

As cases of COVID–19 continue to rise 

across the globe and travel volume 

increases, routine pre-departure testing 

of all U.S.-bound aircraft passengers is 

needed not only to reduce introduction 

of the two known SARS–CoV–2 variants 

from UK and RSA, but also future 

variants that might be more 

transmissible and cause more severe 

illness. 

Action 

For these reasons, I hereby determine 

that passengers covered by this Order 

are at risk of transmitting the new 

SARS–CoV–2 virus variants or other 

potential variants and that requiring 

such passengers to demonstrate either 

negative COVID–19 test results or 

recovery from COVID–19 after previous 

SARS–CoV–2 infection is needed as a 

public health measure to protect the 

health of fellow travelers and U.S. 

communities. 

1. Requirements for Airlines & Other 

Aircraft Operators 

Any airline or other aircraft operator 

with passengers arriving into the United 

States from a foreign country, for each 

passenger onboard the aircraft arriving 

into the United States, shall— 

a. Verify that each passenger has 

attested to having received either a 

negative Qualifying Test result or to 

recovery from COVID–19 after previous 

SARS–CoV–2 infection and clearance to 

travel. Airlines or other aircraft 

operators must retain a copy of each 

passenger attestation for 2 years. The 

attestation is attached to this order as 

Attachment A. 

b. Confirm that each passenger aged 2 

years or older has documentation of a 

negative Qualifying Test result or 

Documentation of Recovery from 

COVID–19. 

c. Not board any passenger without 

verifying the attestation and confirming 

the documentation as set forth in 1.a–b. 

Any airline or other aircraft operator 

that fails to comply with section 1, 

‘‘Requirement for Airlines & Other 

Aircraft Operators,’’ may be subject to 

criminal penalties under, inter alia, 42 

U.S.C. 271 and 42 CFR 71.2, in 

conjunction with 18 U.S.C. 3559 and 

3571. 

2. Requirements for Aircraft Passengers 

Any aircraft passenger departing from 

any foreign country with a destination 

in the United States shall— 

(a) Provide an attestation to the CDC, 

through the airline or other aircraft 

Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 7391 

operator, of having received a negative 

Qualifying Test result or of recovery 

from COVID–19 after previous SARS– 

CoV–2 infection and clearance to travel. 

The attestation is attached to this order 

as Attachment A. Unless otherwise 

permitted by law, a parent or other 

authorized individual should attest on 

behalf of a passenger aged 2 to 17 years. 

An authorized individual may attest on 

behalf to any passenger who is unable 

to attest on his or her own behalf (e.g., 

by reason of physical or mental 

impairment). 

(b) Retain a copy of the negative 

Qualifying Test result or Documentation 

of Recovery from COVID–19 in his/her 

possession and present it for inspection 

to the airline and upon request by an 

agent of the U.S. government or a 

cooperating state or local public health 

authority. 

Any passenger who fails to comply 

with the requirements of section 2, 

‘‘Requirements for Aircraft Passengers,’’ 

may be subject to criminal penalties 

under, inter alia, 42 U.S.C. 271 and 42 

CFR71.2, in conjunction with 18 U.S.C. 

3559 and 3571. Willfully giving false or 

misleading information to the 

government may result in criminal 

penalties under, inter alia, 18 U.S.C. 

1001. 

CDC may modify this Order by an 

updated publication in the Federal 

Register or by posting an advisory to 

follow at www.cdc.gov. 

This Order shall be enforceable 

through the provisions of 18 U.S.C. 

3559, 3571; 42 U.S.C. 243, 268, 271; and 

42 CFR71.2. 

Effective Date 

This Order shall enter into effect on 

January 26, 2021 and shall remain in 

effect until the earliest of (1) the 

expiration of the Secretary of Health and 

Human Services’ declaration that 

COVID–19 constitutes a public health 

emergency; (2) the CDC Director 

rescinds or modifies the order based on 

specific public health or other 

considerations; or (3) December 31, 

2021. 

Authority 

The authority for these orders is 

Sections 361 and 365 of the Public 

Health Service Act (42 U.S.C. 264) and 

42 CFR 71.20 & 71.31(b). 

Dated: January 26, 2021. 

Sherri Berger, 

Acting Chief of Staff, Centers for Disease 

Control and Prevention. 

[FR Doc. 2021–01977 Filed 1–26–21; 4:15 pm] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Board on Radiation and 

Worker Health (ABRWH), National 

Institute for Occupational Safety and 

Health (NIOSH); Correction 

Notice is hereby given of a change in 

the meeting of the Advisory Board on 

Radiation and Worker Health (ABRWH), 

National Institute for Occupational 

Safety and Health (NIOSH); February 

24, 2021, 10:30 a.m. to 4:00 p.m., EST 

which was published in the Federal 

Register on December 23, 2020, Volume 

85, Number 247, page 83964. 

The Matters to be Considered should 

read as follows: 

SUPPLEMENTARY INFORMATION: 

Matters to be Considered: The agenda 

will include discussions on: Work 

Group and Subcommittee Reports; 

Update on the Status of SEC Petitions; 

and plans for the April 2021 Advisory 

Board Meeting. Agenda items are 

subject to change as priorities dictate. 

FOR FURTHER INFORMATION CONTACT: 

Rashaun Roberts, Ph.D., Designated 

Federal Officer, NIOSH, CDC, 1090 

Tusculum Avenue, Mailstop C–24, 

Cincinnati, Ohio 45226, Telephone 

(513) 533–6800, Toll Free 1(800)CDC– 

INFO, Email ocas@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–01889 Filed 1–27–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–20QJ] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled National Survey 

of Community-Based Survey of 

Supports for Healthy Eating and Active 

Living (CBS HEAL) to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on July 20, 

2020 to obtain comments from the 

public and affected agencies. CDC 

received three comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies’ estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication.